205 related articles for article (PubMed ID: 31235036)
21. Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings.
Imai R; Ono M; Nishimura N; Suzuki K; Komiyama N; Tamura T
J Thorac Oncol; 2019 Feb; 14(2):e36-e38. PubMed ID: 30391574
[No Abstract] [Full Text] [Related]
22. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
[No Abstract] [Full Text] [Related]
23. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
24. Hyponatremia in a Patient With Cancer.
Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
[No Abstract] [Full Text] [Related]
25. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
[No Abstract] [Full Text] [Related]
26. Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Osman GA; Marra A; Iacono D; Giannelli V; Ricciardi S; Remotti D; Vecchione A; Ricci A; Palange P; Migliorino MR
Anticancer Drugs; 2019 Aug; 30(7):e0764. PubMed ID: 30950836
[TBL] [Abstract][Full Text] [Related]
27. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
Yonenobu Y; Ishijima M; Toyooka K; Fujimura H
Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688
[TBL] [Abstract][Full Text] [Related]
28. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
[TBL] [Abstract][Full Text] [Related]
29. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
Boozalis E; Kwatra SG; Marrone KA
JAMA Oncol; 2019 Feb; 5(2):261-262. PubMed ID: 30286225
[No Abstract] [Full Text] [Related]
30. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
31. Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
Hirabae A; Ichihara E; Sunami R; Ota M; Iwamoto Y; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):423-425. PubMed ID: 33106698
[TBL] [Abstract][Full Text] [Related]
32. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
33. Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
Khalife N; Kordahi M; Felefly T; Saleh K
Future Oncol; 2021 Jul; 17(20):2559-2562. PubMed ID: 34047193
[No Abstract] [Full Text] [Related]
34. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
Facchinetti F; Majori M; Sabato M; Gnetti L; Tiseo M
Immunotherapy; 2019 Feb; 11(3):161-166. PubMed ID: 30730279
[TBL] [Abstract][Full Text] [Related]
35. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
36. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
37. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
38. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
39. Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report.
Nozawa Y; Oka Y; Oosugi J; Takemura S
Medicine (Baltimore); 2018 May; 97(19):e0718. PubMed ID: 29742733
[TBL] [Abstract][Full Text] [Related]
40. NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
Umeweni N; Knight H; McVeigh G
Lancet Oncol; 2016 Nov; 17(11):1483-1484. PubMed ID: 27692477
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
